Loading...

Fate Therapeutics

Nasdaq:FATE
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FATE
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Fate Therapeutics has significant price volatility in the past 3 months.
FATE Share Price and Events
7 Day Returns
-3.7%
NasdaqGM:FATE
1%
US Biotechs
0.2%
US Market
1 Year Returns
62.8%
NasdaqGM:FATE
-4.6%
US Biotechs
2.9%
US Market
FATE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fate Therapeutics (FATE) -3.7% 11.1% 30.5% 62.8% 1098.7% 171.2%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • FATE outperformed the Biotechs industry which returned -4.6% over the past year.
  • FATE outperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
FATE
Industry
5yr Volatility vs Market

Value

 Is Fate Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fate Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $18.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fate Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fate Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:FATE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.22
NasdaqGM:FATE Share Price ** NasdaqGM (2019-05-22) in USD $18.82
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fate Therapeutics.

NasdaqGM:FATE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:FATE Share Price ÷ EPS (both in USD)

= 18.82 ÷ -1.22

-15.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fate Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Fate Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Fate Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:FATE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -15.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-0.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fate Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fate Therapeutics's assets?
Raw Data
NasdaqGM:FATE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.24
NasdaqGM:FATE Share Price * NasdaqGM (2019-05-22) in USD $18.82
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqGM:FATE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:FATE Share Price ÷ Book Value per Share (both in USD)

= 18.82 ÷ 2.24

8.4x

* Primary Listing of Fate Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fate Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Fate Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Fate Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Fate Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-0.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fate Therapeutics expected to grow at an attractive rate?
  • Unable to compare Fate Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Fate Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Fate Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:FATE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:FATE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -0.5%
NasdaqGM:FATE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 65.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:FATE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:FATE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 141 -225 -91 4
2022-12-31 80 -201 -86 4
2021-12-31 32 -133 -97 4
2020-12-31 15 -83 -99 6
2019-12-31 7 -78 -89 6
NasdaqGM:FATE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 6 -44 -72
2018-12-31 5 -39 -67
2018-09-30 4 -38 -63
2018-06-30 4 -45 -57
2018-03-31 4 -42 -47
2017-12-31 4 -37 -43
2017-09-30 4 -34 -38
2017-06-30 4 -31 -36
2017-03-31 4 -30 -35
2016-12-31 4 -30 -33
2016-09-30 4 -29 -33
2016-06-30 4 -29 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Fate Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Fate Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:FATE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Fate Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:FATE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.83 1.37 -2.41 3.00
2022-12-31 -1.83 -1.28 -2.38 2.00
2021-12-31 -1.26 -0.65 -1.91 4.00
2020-12-31 -1.24 -0.47 -1.68 6.00
2019-12-31 -1.27 -0.86 -1.38 6.00
NasdaqGM:FATE Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.22
2018-12-31 -1.19
2018-09-30 -1.24
2018-06-30 -1.19
2018-03-31 -1.05
2017-12-31 -1.02
2017-09-30 -0.95
2017-06-30 -0.96
2017-03-31 -1.01
2016-12-31 -1.05
2016-09-30 -1.11
2016-06-30 -1.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fate Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Fate Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fate Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Fate Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fate Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fate Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fate Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fate Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Fate Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fate Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:FATE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 6.35 -72.22 17.55
2018-12-31 4.74 -66.60 15.81
2018-09-30 4.11 -63.07 14.89
2018-06-30 4.11 -56.97 13.59
2018-03-31 4.11 -46.96 12.45
2017-12-31 4.11 -42.95 11.87
2017-09-30 4.11 -38.40 10.94
2017-06-30 4.11 -36.45 10.76
2017-03-31 4.11 -35.21 10.34
2016-12-31 4.40 -33.46 9.91
2016-09-30 4.45 -32.97 10.02
2016-06-30 4.45 -31.12 9.76
2016-03-31 3.75 -30.49 10.20
2015-12-31 2.43 -29.99 10.35
2015-09-30 1.36 -28.78 9.88
2015-06-30 0.33 -28.50 9.43
2015-03-31 -26.78 8.81
2014-12-31 -25.88 8.47
2014-09-30 0.00 -25.39 8.26
2014-06-30 0.21 -24.86 8.34
2014-03-31 0.50 -24.33 7.76
2013-12-31 0.97 -20.89 6.64
2013-09-30 1.61 -19.31 6.05
2013-06-30 1.93 -17.35 4.94
2013-03-31 2.72 -14.55 4.47
2012-12-31 2.67 -14.24 4.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fate Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fate Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fate Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fate Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fate Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Fate Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fate Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fate Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fate Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fate Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fate Therapeutics Company Filings, last reported 1 month ago.

NasdaqGM:FATE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 145.84 42.62 183.03
2018-12-31 160.47 14.88 201.01
2018-09-30 173.93 14.87 211.19
2018-06-30 51.83 14.85 78.02
2018-03-31 65.00 14.83 88.63
2017-12-31 77.19 14.81 100.95
2017-09-30 45.75 14.79 69.21
2017-06-30 55.21 6.68 71.01
2017-03-31 63.86 8.70 82.30
2016-12-31 73.15 10.69 92.11
2016-09-30 25.37 12.64 46.62
2016-06-30 23.13 14.54 45.93
2016-03-31 30.73 16.41 55.61
2015-12-31 38.04 18.24 64.81
2015-09-30 45.00 19.13 72.86
2015-06-30 51.07 19.70 81.18
2015-03-31 21.25 19.67 42.35
2014-12-31 28.34 19.61 49.10
2014-09-30 33.58 10.00 45.53
2014-06-30 39.64 0.75 42.01
2014-03-31 45.18 1.24 47.88
2013-12-31 50.85 1.73 54.04
2013-09-30 -9.88 25.70 19.08
2013-06-30 -0.15 2.71 3.40
2013-03-31 0.24 3.19 4.65
2012-12-31 3.70 3.67 9.09
  • Fate Therapeutics's level of debt (29.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.7% vs 29.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fate Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Fate Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 20.9% each year.
X
Financial health checks
We assess Fate Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fate Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Fate Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fate Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Fate Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fate Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fate Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:FATE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:FATE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fate Therapeutics has not reported any payouts.
  • Unable to verify if Fate Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fate Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fate Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Fate Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Fate Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fate Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fate Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Fate Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Wolchko
COMPENSATION $3,530,998
AGE 48
TENURE AS CEO 3.4 years
CEO Bio

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015. Mr. Wolchko served as Principal Financial Officer and Principal Accounting Officer of Fate Therapeutics, Inc. He serves as the Chief Financial Officer and served as Chief Operations Officer of Fate Therapeutics, Inc. from February 2013 to November 30, 2015. Mr. Wolchko serves as Treasurer and Secretary at Fate Therapeutics, Inc., Mr. Wolchko served as Principal Accounting Officer Treasurer and Secretary at Fate Therapeutics, Inc., and was responsible for financial and business development activities. He served as Vice President of Operations of Fate Therapeutics, Inc. He served as the Chief Financial Officer of Bocada, Inc. Prior to joining Bocada Inc. He has been a Director at Fate Therapeutics, Inc. since October 2015. Mr. Wolchko served as Senior Director of Corporate Development for drugstore.com, where he was responsible for evaluating and executing financial and business development opportunities. Previously, he served in the Investment Banking Division of Morgan Stanley & Co.'s New York City and Menlo Park, California offices for six years. As a member of Morgan Stanley & Co.'s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and strategic transactions. Mr. Wolchko holds an M.S. in Biochemical Engineering from the University of Virginia and a B.S. in Biomedical Engineering from the University of Vermont.

CEO Compensation
  • J.'s compensation has increased whilst company is loss making.
  • J.'s remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Fate Therapeutics management team in years:

1.7
Average Tenure
46.5
Average Age
  • The average tenure for the Fate Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

J. Wolchko

TITLE
Founder
COMPENSATION
$4M
AGE
48
TENURE
3.4 yrs

Dan Shoemaker

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
50
TENURE
4 yrs

Cindy Tahl

TITLE
General Counsel & Compliance Officer
COMPENSATION
$1M
AGE
45
TENURE
3.6 yrs

Bob Valamehr

TITLE
Chief Development Officer
COMPENSATION
$3M
AGE
41
TENURE
1.3 yrs

Wen Wang

TITLE
Senior Vice President of Technical Operations
TENURE
0.6 yrs

Jim Beitel

TITLE
Senior Vice President of Corporate Development
TENURE
1.7 yrs

Sarah Cooley

TITLE
Senior Vice President of Clinical Translation
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Fate Therapeutics board of directors in years:

8.3
Average Tenure
58
Average Age
  • The tenure for the Fate Therapeutics board of directors is about average.
Board of Directors

Bill Rastetter

TITLE
Chairman
COMPENSATION
$194K
AGE
70
TENURE
7.5 yrs

J. Wolchko

TITLE
Founder
COMPENSATION
$4M
AGE
48
TENURE
3.6 yrs

John Mendlein

TITLE
Vice Chairman of the Board
COMPENSATION
$153K
AGE
58
TENURE
7.5 yrs

Tim Coughlin

TITLE
Director
COMPENSATION
$163K
AGE
51
TENURE
5.8 yrs

Ben Shapiro

TITLE
Member of Scientific Advisory Board
AGE
78

Amir Nashat

TITLE
Director
COMPENSATION
$146K
AGE
45
TENURE
11.7 yrs

Bob Langer

TITLE
Member of Scientific Advisory Board
AGE
69

Stuart Orkin

TITLE
Member of Scientific Advisory Board
TENURE
9 yrs

Sean Morrison

TITLE
Member of Scientific Advisory Board
TENURE
9 yrs

Mark Krasnow

TITLE
Member of Scientific Advisory Board
TENURE
9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Feb 19 Sell Polaris Partners Company 30. Jan 19 30. Jan 19 -53,017 $14.16 $-750,959
31. Jan 19 Sell Polaris Partners Company 29. Jan 19 29. Jan 19 -97,500 $14.16 $-1,380,795
30. Jan 19 Sell Polaris Partners Company 28. Jan 19 28. Jan 19 -70,000 $13.78 $-964,768
29. Jan 19 Sell Polaris Partners Company 25. Jan 19 25. Jan 19 -90,000 $14.14 $-1,272,753
23. Jan 19 Sell Polaris Partners Company 18. Jan 19 18. Jan 19 -39,483 $16.28 $-642,834
26. Dec 18 Sell Polaris Partners Company 20. Dec 18 20. Dec 18 -33,474 $12.25 $-410,160
21. Dec 18 Sell Polaris Partners Company 19. Dec 18 19. Dec 18 -91,210 $13.96 $-1,222,592
17. Dec 18 Sell Polaris Partners Company 13. Dec 18 13. Dec 18 -17,788 $16.67 $-296,563
14. Dec 18 Sell Polaris Partners Company 12. Dec 18 12. Dec 18 -425,000 $16.78 $-7,132,690
13. Dec 18 Sell Polaris Partners Company 11. Dec 18 11. Dec 18 -82,528 $16.71 $-1,379,183
27. Sep 18 Buy Redmile Group, LLC Company 25. Sep 18 25. Sep 18 3,703,704 $13.50 $50,000,004
X
Management checks
We assess Fate Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fate Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did You Miss Fate Therapeutics's (NASDAQ:FATE) Whopping 678% Share Price Gain?

Because Fate Therapeutics is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … In the last 3 years Fate Therapeutics saw its revenue grow at 6.8% per year.

Simply Wall St -

Should You Be Pleased About The CEO Pay At Fate Therapeutics, Inc.'s (NASDAQ:FATE)

First, this article will compare CEO compensation with compensation at similar sized companies. … Wolchko's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$1.1b, and pays its CEO total annual compensation worth US$1.3m.

Simply Wall St -

How Many Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Do Institutions Own?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … Companies that used to be publicly owned tend to have lower insider ownership. … With a market capitalization of US$979m, Fate Therapeutics is a decent size, so it is probably on the radar of institutional investors.

Simply Wall St -

Does Fate Therapeutics Inc (NASDAQ:FATE) Go Up With The Market?

The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

Loss-Making Fate Therapeutics Inc (NASDAQ:FATE) Expected To Breakeven

Fate Therapeutics Inc's (NASDAQ:FATE):. … The company’s loss has recently broadened since it announced a -US$42.95m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$46.96m, moving it further away from breakeven … Many investors are wondering the rate at which FATE will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Fate Therapeutics Inc (NASDAQ:FATE): Does -16.46% Earnings Drop In A Year Reflect The Long-Term Trend?

In this commentary, I will examine Fate Therapeutics Inc's (NASDAQ:FATE) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, as well as how the rest of the biotechs industry performed. … NasdaqGM:FATE Income Statement Jan 22nd 18 Additionally, we can assess Fate Therapeutics's loss by looking at what’s going on in the industry as well as within the company. … This suggests that any tailwind the industry is profiting from, Fate Therapeutics has not been able to gain as much as its industry peers.What does this mean?

Simply Wall St -

What Are Analysts Expecting From Fate Therapeutics Inc (FATE) Over The Couple Of Years?

Fate Therapeutics Inc's (NASDAQ:FATE) latest earnings announcement in September 2017 revealed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Investors may find it useful to understand how market analysts view Fate Therapeutics's earnings growth trajectory over the next couple of years and whether the future looks brighter. … View our latest analysis for Fate Therapeutics Market analysts' consensus outlook for next year seems pessimistic, with earnings becoming even more negative, arriving at $-45.4M in 2018. … NasdaqGM:FATE Future Profit Dec 6th 17 Even though it’s helpful to understand the growth rate year by year relative to today’s level, it may be more insightful to evaluate the rate at which the earnings are rising or falling on average every year.

Simply Wall St -

Company Info

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company’s immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Details
Name: Fate Therapeutics, Inc.
FATE
Exchange: NasdaqGM
Founded: 2007
$1,226,797,395
65,185,834
Website: http://www.fatetherapeutics.com
Address: Fate Therapeutics, Inc.
3535 General Atomics Court,
Suite 200,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM FATE Common Stock Nasdaq Global Market US USD 01. Oct 2013
DB F6T Common Stock Deutsche Boerse AG DE EUR 01. Oct 2013
Number of employees
Current staff
Staff numbers
104
Fate Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 06:22
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.